Nuvectis Pharma Q2 FY26 net loss widens to USD 7.02 millionPUBT·Aug 4 at 07:08 AMNVCT+8.15%002653-0.78%
Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patientsPUBT·Jul 23 at 06:32 AMNVCT+8.15%002653-0.78%
China's Haisco Gets China’s Nod for Rare Blood Disorder DrugYicai·Jul 23 at 06:27 AM002653-0.78%NVCT+8.15%
02:08 ETHaisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNHprnewswire·Jul 23 at 01:10 AM002653-0.78%
Haisco and Nuvectis sign licensing deal for two drugsPharmaceutical Technology·Jun 24 at 03:10 AMNVCT+8.15%002653-0.78%
Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement IndicationsUnusual Whales·Jun 23 at 08:20 AM002653-0.78%NVCT+8.15%
Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trendingbenzinga_article·Jun 23 at 01:30 AMNVCT+8.15%002653-0.78%
Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLArttnews·Jun 22 at 10:15 PMAZTR-5.25%FTH+2.26%
Nuvectis Pharma shares are trading higher after the company announced a strategic portfolio expansion with Haisco Pharmaceutical Group. Also, HC Wainwright & Co raised its price target on the stock from $13 to $39.benzinga_article·Jun 22 at 12:38 PMNVCT+8.15%002653-0.78%
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds | NVCT Stock NewsStockTitan·Jun 21 at 10:30 PMNVCT+8.15%002653-0.78%
Chinese Innovative Drugmaker Haisco Inks USD3 Billion R&D Deal With Eli LillyYicai·Jun 1 at 10:30 PM002653-0.78%LLY+3.70%
Eli Lilly Deepens Innovation Push Through New Biopharma Collaborationsbenzinga_article·Jun 1 at 12:19 PMLLY+3.70%002653-0.78%
Lilly Continues Its Acquisition Spree, Inks Two Asia Partnerships Todayrttnews·Jun 1 at 11:25 AMLLY+3.70%002653-0.78%
Haisco Announces Licensing and Research Collaboration Agreement with Lilly to Develop Innovative Medicines Across Multiple Therapeutic AreasPR Newswire·Jun 1 at 04:50 AM002653-0.78%LLY+3.70%
China's Original Innovative Drug Cipepofol Approved for Marketing by the U.S. FDAPR Newswire·Jun 1 at 02:04 AM002653-0.78%
